Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective

Johan Jendlea Institute of Medical Sciences, Örebro University, Örebro, SwedenCorrespondence[email protected]

https://orcid.org/0000-0003-1025-1682

Åsa Ericssonb Novo Nordisk Scandinavia AB, Malmö, Sweden

Bertil Ekmanc Department of Endocrinology, and Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden

https://orcid.org/0000-0001-8732-7361

Stefan Sjöbergd Department of Medicine, Karolinska Huddinge University Hospital, Stockholm, Sweden

Jens Gundgaarde Novo Nordisk A/S, Søborg, Denmark

João da Rocha Fernandese Novo Nordisk A/S, Søborg, Denmark

Ann-Charlotte Mårdbyb Novo Nordisk Scandinavia AB, Malmö, Sweden

https://orcid.org/0000-0003-0579-3583

Barnaby Huntf Ossian Health Economics and Communications, Basel, Switzerland

https://orcid.org/0000-0001-5420-279X

Samuel J. P. Malkinf Ossian Health Economics and Communications, Basel, Switzerland

https://orcid.org/0000-0003-1306-7784

Maria Thunanderf Department of Clinical Sciences, Endocrinology and Diabetes, Lund University, Lund, Sweden

https://orcid.org/0000-0001-6888-1295

show all

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Articles from other publishers (7)

Eden Avnat, Gabriel Chodick & Varda Shalev. (2023) Identifying Profiles of Patients with Uncontrolled Type 2 Diabetes Who Would Benefit from Referral to an Endocrinologist. Endocrine Practice.
Crossref

Wanqin Hu, Chunxia Zhai, Hongyu Sun, XingYu Gong, Liangyu Cui, Lin Cai, Qiqun Zong, Guanghui Yu, Fang Wang & Yanfeng Zou. (2023) The global burden of disease attributable to metabolic risks in 204 countries and territories from 1990 to 2019. Diabetes Research and Clinical Practice 196, pages 110260.
Crossref

. (2022) Erratum. Journal of Wound Care 31:Sup2, pages S31-S31.
Crossref

William H Tettelbach, David G Armstrong, Thomas J Chang, Julie L De Jong, Paul M Glat, Jeffrey H Hsu, Martha R Kelso, Jeffrey A Niezgoda, Jonathan M Labovitz, Brandon Hubbs, R Allyn Forsyth, Benjamin G Cohen, Natalie M Reid & William V Padula. (2022) Cost-effectiveness of dehydrated human amnion/chorion membrane allografts in lower extremity diabetic ulcer treatment. Journal of Wound Care 31:Sup2, pages S10-S31.
Crossref

Ileana Mardare, Stephen M. Campbell, Johanna C. Meyer, Israel Abebrese Sefah, Amos Massele & Brian Godman. (2022) Enhancing Choices Regarding the Administration of Insulin Among Patients With Diabetes Requiring Insulin Across Countries and Implications for Future Care. Frontiers in Pharmacology 12.
Crossref

Brian Godman, Magdalene Wladysiuk, Stuart McTaggart, Amanj Kurdi, Eleonora Allocati, Mihajlo Jakovljevic, Francis Kalemeera, Iris Hoxha, Anna Nachtnebel, Robert Sauermann, Manfred Hinteregger, Vanda Marković-Peković, Biljana Tubic, Guenka Petrova, Konstantin Tachkov, Juraj Slabý, Radka Nejezchlebova, Iva Selke Krulichová, Ott Laius, Gisbert Selke, Irene Langner, András Harsanyi, András Inotai, Arianit Jakupi, Svens Henkuzens, Kristina Garuolienė, Jolanta Gulbinovič, Patricia Vella Bonanno, Jakub Rutkowski, Skule Ingeberg, Øyvind Melien, Ileana Mardare, Jurij Fürst, Sean MacBride-Stewart, Carol Holmes, Caridad Pontes, Corinne Zara, Marta Turu Pedrola, Mikael Hoffmann, Vasileios Kourafalos, Alice Pisana, Rita Banzi, Stephen Campbell & Bjorn Wettermark. (2021) Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications. BioMed Research International 2021, pages 1-16.
Crossref

Margareta Hellgren, Ann‐Marie Svensson, Stefan Franzén, Åsa Ericsson, Soffia Gudbjörnsdottir, Nils Ekström, Rebecka Bertilsson, William Valentine & Samuel Malkin. (2021) The burden of poor glycaemic control in people with newly diagnosed type 2 diabetes in Sweden : A health economic modelling analysis based on nationwide data . Diabetes, Obesity and Metabolism 23:7, pages 1604-1613.
Crossref

Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective

Articles from other publishers (7)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective

Citations (7)

Articles from other publishers (7)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date